| ¿µ¹® | Dilatation and Curettage(D & C) | ÇÑ±Û | Àڱñܾ¼ú, ÀڱøñÈ®Àå |
|---|---|---|---|
| ¼³¸í | ÀÚ±ÃÀ̶õ žư¡ ¼öÅÂµÇ¾î¼ ºÐ¸¸Àü±îÁö ¹ßÀ°ÇÏ°í ¼ºÀåÇÏ´Â °ø°£ÀÌ´Ù. Àڱüӿ¡ º´º¯ÀÌ ÀÖ¾î ÀÓ½ÅÀÌ °è¼ÓµÉ ¼ö ¾ø°Å³ª ¾Æ´Ï¸é ´Ù¸¥ ÀÌÀ¯·Î ÀӽŵǾî Àִ žƸ¦ Á¦°ÅÇϰíÀÚ ÇÒ °æ¿ì¿¡ »ç¿ëµÇ´Â ¹æ¹ýÀÌ´Ù. ¿©±â¼ ±Ü¾î³»±â À§ÇÏ¿©´Â ¿ì¼± ÀÚ±ÃÀÇ ÀÔ±¸¿¡ ÇØ´çÇÏ´Â ÀڱøñÀ» È®Àå½ÃÄÑ¾ß ÇÑ´Ù. ¿©±â¿¡´Â ±Þ¼ÓÈ÷ È®ÀåÀ» ½ÃµµÇÏ´Â ¹ý°ú ¼¼È÷ È®ÀåÀ» ½ÃµµÇÏ´Â 2°¡Áö ¹æ¹ýÀÌ ÀÖ´Ù. ÀڱøñÀ» ±Þ¼ÓÈ÷ È®ÀåÇÒ ¶§´Â Çì°¡¸£ ¸ñ°üÈ®Àå±â(Hegar's dilatator)¸¦ »ç¿ëÇÑ´Ù. À̰ÍÀº ÀÛÀº ±Ý¼Ó¸·´ë·Î ÀÛÀº Å©±âºÎÅÍ Å« Å©±â±îÁö ´Ù¾çÇÑ Å©±â°¡ ÀÖ¾î¼ ¿ì¼± ÀÛÀº ¸·´ë·Î ½ÃÀÛÇÏ¿© Á¡Á¡ Å« Å©±âÀÇ ¸·´ë¸¦ Àڱøñ¿¡ ³Ö¾î¼ ÀڱøñÀ» È®Àå½ÃŲ´Ù. ¼¼È÷ È®Àå½Ãų ¶§´Â Laminaria tent¸¦ ¸ñ°ü¿¡ »ðÀÔÇÏ´Â ¹æ¹ýÀ» »ç¿ëÇÑ´Ù. Laminaria tent¶õ ÇØÃÊ·Î ¸¸µç ÀÛÀº ¸·´ë·Î ¼öºÐÀ» Èí¼öÇϸé Á¡Á¡ ´Ã¾î³ª´Â ¼ºÁúÀÌ ÀÖ´Ù. À̰ÍÀ» ÀÚ±ÃÀÇ ¸ñ¿¡ ³ÖÀ¸¸é À̰ÍÀÌ ¼öºÐÀ» Èí¼öÇÏ¿© ´Ã¾î³ª¹Ç·Î õõÈ÷ ÀÚ±ÃÀÇ ¸ñÀÌ ´Ã¾î³´Ù. ÀڱøñÀÌ ÃæºÐÈ÷ ´Ã¾î³ª¸é ±× ¼ÓÀ¸·Î ³¡ÀÌ ¼ù°¡¶ôó·³ »ý±ä ±â±¸¸¦ ³Ö¾î¼ ÀڱüÓÀÇ º´º¯À̳ª ÀÓ½ÅµÈ Å¾Ƹ¦ ±Ü¾î³»´Âµ¥ ¿©±â¿¡ »ç¿ëµÇ´Â ¼ù°¡¶ôó·³ »ý±ä ±â±¸¸¦ Å¥·¿À̶ó°í ÇÑ´Ù. Ãʱâ ÀÓ½ÅÁßÀý Áï À¯»ê°ú °°Àº ÀӽŰú °ü·ÃµÈ °æ¿ì»Ó¸¸ ¾Æ´Ï¶ó, ºñÀӽŠÀÚ±ÃÀÇ Àڱ󻸷Á¶Á÷ÀÇ Ã¤Ãë ¹× Á¦°Å¸¦ À§Çؼµµ ÇàÇØÁö´Â ¼ö±âÀÌ´Ù. ÀÌ´Â ¿øÄ¢ÀûÀ¸·Î ¸¶ÃëÇÏ¿¡ ½Ç½ÃµÇ´Â °ÍÀ¸·Î Àڱøñ°üÀ» È®ÀåÇÏ°í ±â±¸·Î Àڱà ³»¿ë¹°À» Á¦°ÅÇϰí Å¥·¿À¸·Î Àڱ󻺮À» ±ú²ýÀÌ ÇÑ´Ù. ÀÚ±Ãõ°øÀ̳ª ÀڱøñÀÇ ÆÄ¿ µîÀÇ À§ÇèÀÌ µû¸£¸ç, ¼ö¼úÈÄ °¨¿° ¶Ç´Â ÃâÇ÷ µî¿¡ ´ëÇÑ ÁÖÀǰ¡ ÇÊ¿äÇÏ´Ù. |
||
| ¿µ¹® | prostate gland | ÇÑ±Û | Àü¸³»ù |
|---|---|---|---|
| ¼³¸í | ³²¼º»ý½Ä±âÀÇ ¿ÜºÐºñ»ùÀÇ ÀÏÁ¾À¸·Î, ¹æ±¤ÀÇ ¸ñºÎºÐ°ú ¿äµµ¸¦ µÑ·¯½Î°í ÀÖ´Ù. Àü¸³»ùÀº Á¤¾×À» ¸¸µå´Â Àü¸³»ù¾×À» ºÐºñÇϸç 5°³ÀÇ ¿±À¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. |
||
| ¿µ¹® | Benign Prostatic Hyperplasia(BPH) | ÇÑ±Û | Àü¸³»ùºñ´ë |
|---|---|---|---|
| ¼³¸í | 50¼¼ ÀÌ»óÀÇ ³²¼º¿¡ ºó¹ßÇÏ´Â º´À¸·Î Àü¸³»ùÀÇ ¿äµµ ÁÖÀ§ ¿µ¿ª¿¡ Å«°áÀýÀ» Çü¼ºÇÏ¿©, À̰ÍÀÌ Ä¿Áö¸é ¿äµµ¸¦ ¾Ð¹ÚÇÏ¿© ºÎºÐÀû ȤÀº ¿ÏÀüÇÑ ¿äµµÆó»öÀ» ÀÏÀ¸Å°´Â º´ÀÌ´Ù. Áõ»óÀº ¿äµµÆó»ö¿¡ µû¸¥ ¼Òº¯ÀÇ °¨¼Ò¿Í ¹æ±¤ÀÚ±ØÁõ»óÀ¸·Î ºó´¢, ÀÜ´¢°¨, ¼Òº¯À» ÂüÀ» ¼ö ¾ø´Â Áõ»ó µîÀÌ´Ù. Ä¡·á´Â °æ¿äµµ Àü¸³»ù ÀûÃâ¼ú·Î Àü¸³¼±ÀÇ ºñ´ëÇÑ ºÎºÐÀ» ÀýÁ¦ÇØ¾ß ÇÑ´Ù. |
||
| ¿µ¹® | venereal disease, sexually transmitted diseases | ÇÑ±Û | ¼ºº´ |
|---|---|---|---|
| ¼³¸í | º¸ÆíÀûÀ¸·Î ¼º±³ ¶Ç´Â ¼º±âÁ¢ÃË¿¡ ÀÇÇØ °É¸®´Â Á¢ÃË Àü¿°º´À¸·Î ¸Åµ¶, ÀÓÁú, ¹«¸¥±Ë¾ç, »ô±¼À°¾ÆÁ¾ µîÀ» ¸»ÇÑ´Ù. Ä¡·á´Â ¿øÀαտ¡ µû¸¥ ÀûÀýÇÑ Ç×»ý¿ä¹ýÀÌ´Ù. |
||
| ¿µ¹® | psychosomatic diseases | ÇÑ±Û | Á¤½Å½ÅüÁúȯ |
|---|---|---|---|
| ¼³¸í | ¿©·¯ °¡Áö Á¤½ÅÀûÀÎ ¿øÀο¡ ÀÇÇÑ ½Åü Áõ»óÀ» Ư¡À¸·Î ÇÏ´Â Á¤½ÅÁúȯ°ú ½Åü ÁúȯÀÇ È¥ÇÕÇüÀ» À̸£´Â ¸»·Î, Á¤½Å ÁúȯÀÇ ¿©·¯ °¡Áö Áõ»óÀÌ ½Åü Áõ»óÀ¸·Î ¹ßÇöµÇ´Â ÁúȯÀÌ´Ù. ½Åü Áõ»óÀº ¿©·¯ ´Ù¾çÇÑ Àå±â°¡ °ü¿©Çϰųª ¶Ç´Â ÇÑ Àå±â¸¸ °ü¿©ÇÑ´Ù. |
||
| ICD | I-cell disease; immune complex disease; implantable cardioverter defibrillator; impulse-control diso... |
|---|---|
| BPH | Benign Prostate(Prostatic) Hypertrophy(Hyperplasia); Àü¸³¼± ºñ´ë(Áõ) |
| PSA | Prostate(Prostatic)-Specific Antigen; Àü¸³¼± ƯÀÌ Ç׿ø |
| pros | prostate, prostatic |
| AFP | Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265] ; Oncofetal Antigens &nbs... |
| NPCP | National Prostatic Cancer Project |
|---|---|
| PC | Prostatic cancer |
| PCA | prostatic cancer |
| HRPC | Hormone refractory prostate cancer |
| PC | Prostate Cancer |
| cancer, prostatic | Cancer of the gland (prostate) that produces some of the components of semen fluid. The second leading cause of death of males in the U.S. Prostate cancer is often first detected as a hard nodule during a routine rectal examination. The PSA blood test is a screening test for prostate cancer. Diagnosis of prostate cancer is established when cancer cells are identified in prostate tissue obtained by a biopsy. In some patients, prostate cancer is life threatening. In many others, prostate cancer can exist for years without causing any health problems. Treatment options for prostate cancer include observation, radiation therapy, surgery, hormonal therapy, and chemotherapy. (12 Dec 1998) |
|---|---|
| cancer, prostate | Cancer of the gland that produces some of the components of semen fluid. Prostate cancer is the second leading cause of death of males in the U.S. Prostate cancer is often first detected as a hard nodule during a routine rectal examination. The PSA blood test is a screening test for prostate cancer. Diagnosis of prostate cancer is established when cancer cells are identified in prostate tissue obtained by a biopsy. In some patients, prostate cancer is life threatening. In many others, prostate cancer can exist for years without causing any health problems. Treatment options for prostate cancer include observation, radiation therapy, surgery, hormonal therapy, and chemotherapy. (12 Dec 1998) |
| prostate cancer | The second most common malignancy in men. A malignant tumour of glandular origin in the prostate. Over 95% are adenocarcinomas. Most commonly seen in older men, with the age of 73 being the average age at the time of diagnosis. A family history for prostate cancer and perhaps, a diet that is high is fat are considered to be risk factors for this malignancy. Early detection is possible through annual digital rectal examinations and routine PSA testing. (27 Sep 1997) |
| hemic and lymphatic diseases | Haematologic diseases and diseases of the lymphatic system collectively. Hemic diseases include disorders involving the formed elements (e.g., erythrocyte aggregation, intravascular) and chemical components (e.g., blood protein disorders); lymphatic diseases include disorders relating to lymph, lymph nodes, and lymphocytes. (12 Dec 1998) |
| skin and connective tissue diseases | A collective term for diseases of the skin and its appendages and of connective tissue. (12 Dec 1998) |
| neonatal diseases and abnormalities | Diseases existing at birth and often before birth, regardless of causation. Of these congenital diseases, those characterised by structural deformities are termed abnormalities. (12 Dec 1998) |
| nutritional and metabolic diseases | A collective term for nutritional disorders (result of poor assimilation or utilization of food) and metabolic disorders (result of poor metabolism or inherited enzyme abnormality). (12 Dec 1998) |
| injuries, poisonings, and occupational diseases | Disorders representing collectively the results of assault by external forces, rather than by organic or physiologic dysfunction or by pathogens. (12 Dec 1998) |
| urologic and male genital diseases | A collective term for urinary tract diseases in male and female and diseases of the male genitalia. (12 Dec 1998) |
| cancer, colon: screening and surveillance | Colon cancer is both preventable and curable. It is preventable by removing precancerous colon polyps. It is curable if early cancer is surgically removed before cancer spread to other parts of the body. Therefore, if screening and surveillance programs were practiced universally, there would be a major reduction in the incidence and mortality of colon cancer. (12 Dec 1998) |
| colon cancer and polyps | Benign tumours of the large intestine are called polyps. Malignant tumours of the large intestine are called cancers. Benign polyps do not invade nearby tissue or spread to other parts of the body. Benign polyps can be easily removed during colonoscopy, and are not life threatening. If benign polyps are not removed from the large intestine, they can become malignant (cancerous) over time. most of the cancers of the large intestine are believed to have developed from polyps. (12 Dec 1998) |
| benign prostatic hyperplasia | <urology> A benign enlargement of the prostate gland begins normally after age 50 years probably secondary to the effects of male hormones. If significant enlargement occurs, it may pinch off te urethra making urination difficult or impossible. See: urinary retention. Origin: Gr. Plassein = to form (06 Aug 1998) |
| benign prostatic hypertrophy | <urology> A benign enlargement of the prostate gland begins normally after age 50 years probably secondary to the effects of male hormones. If significant enlargement occurs, it may pinch off te urethra making urination difficult or impossible. See: urinary retention. (06 Aug 1998) |
| prostatic | <anatomy> Of or pertaining to the prostate gland. Source: Websters Dictionary (01 Mar 1998) |
| prostatic adenoma | <tumour> A term used for the growth in benign prostatic hyperplasia. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|